THANK YOU FOR SUBSCRIBING
Lantheus recognizes the potential improvements in image quality and ability to quantify tissue perfusion and additional physiological information impacting medical treatment and outcomes in the overall population and particularly in those still underserved. They have since established a portfolio of three internally-discovered imaging agents in clinical and preclinical development, each of which has the potential to significantly enhance current imaging modalities and execute unmet diagnostic medical imaging needs. Presently, their Positron Emission Tomography (PET), Myocardial Perfusion Imaging (MPI) agent, and Flurpiridaz F 18, are in Phase 3 clinical studies.
The company’s commitment towards healthcare and innovation has been solidified with the approval and launch of one of their most successful radiopharmaceutical— Cardiolite. A myocardial perfusion agent, Cardolite is used at indicating and detecting coronary artery disease by localizing myocardial ischemia-reversible defects and infarction-non-reversible defects, in evaluating myocardial function and developing information for use in patient management decisions. Lantheus uses Cardiolite evaluation of myocardial ischemia to accomplish cardiovascular stress techniques, for example: pharmacologic stress in accordance with the pharmacologic stress agent’s labeling. Cardiolite became the first technetium-labeled myocardial perfusion imaging tracer to provide physicians with prognostic information helpful in making patient management decisions related to coronary artery disease.
We will continue to provide industry-leading nuclear medicine products and contrast agents to healthcare providers and their patients for the years to come
Advancing the art and science of imaging, Lantheus is developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging. The company believes their pipeline products have the potential to significantly enhance current imaging modalities and fulfill unmet diagnostic medical imaging needs. Lantheus' pipeline agents include Flurpiridaz F 18—a MPI agent, Cardiac Neuronal Agent (CNA)—that allows better identification of patients at risk of Sudden Cardiac Death (SCD) alongside Vascular Remodeling Imaging—used to risk stratify patients for potential vascular events, including heart attack or stroke.
Lantheus continues to enhance current imaging modalities and fulfill unmet diagnostic medical imaging needs. In addition to their diversified portfolio of commercialized imaging agents and products, the company has a strong development pipeline of internally-discovered next generation, first-in-class imaging agents that use PET and MRI technologies focused on developing the present imaging modalities. “We will continue to provide industry-leading nuclear medicine products and contrast agents to healthcare providers and their patients for the years to come,” says Mary Anne Heino, President and CEO of Lantheus.